155 related articles for article (PubMed ID: 8969375)
41. An Adjusted Calculation Model of Reduced Heparin Doses in Cardiopulmonary Bypass Surgery in a Chinese Population.
Zhang Y; Liu K; Li W; Xue Q; Hong J; Xu J; Wu L; Ji G; Sheng J; Wang Z
J Cardiothorac Vasc Anesth; 2016 Oct; 30(5):1179-83. PubMed ID: 27475733
[TBL] [Abstract][Full Text] [Related]
42. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits.
Ranucci M; Cazzaniga A; Soro G; Isgrò G; Frigiola A; Menicanti L
J Cardiothorac Vasc Anesth; 2002 Jun; 16(3):316-20. PubMed ID: 12073203
[TBL] [Abstract][Full Text] [Related]
43. A comparison of low vs conventional-dose heparin for minimal cardiopulmonary bypass in coronary artery bypass grafting surgery.
Fromes Y; Daghildjian K; Caumartin L; Fischer M; Rouquette I; Deleuze P; Bical OM
Anaesthesia; 2011 Jun; 66(6):488-92. PubMed ID: 21501130
[TBL] [Abstract][Full Text] [Related]
44. [The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits].
Yamanaka J; Takeuchi Y; Torii S; Gomi A; Nakatani H; Kohno K
Nihon Kyobu Geka Gakkai Zasshi; 1996 Jan; 44(1):47-53. PubMed ID: 8683171
[TBL] [Abstract][Full Text] [Related]
45. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management.
Weiss BM; von Segesser LK; Turina MI; Seifert B; Pasch T
J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):464-70. PubMed ID: 8776638
[TBL] [Abstract][Full Text] [Related]
46. Heparin-coated cardiopulmonary bypass circuit: clinical effects in pediatric cardiac surgery.
Miyaji K; Hannan RL; Ojito J; Jacobs JP; White JA; Burke RP
J Card Surg; 2000; 15(3):194-8. PubMed ID: 11414605
[TBL] [Abstract][Full Text] [Related]
47. Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting.
Nakahira A; Sasaki Y; Hirai H; Fukui T; Matsuo M; Takahashi Y; Kotani S; Suehiro S
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):555-60. PubMed ID: 20061337
[TBL] [Abstract][Full Text] [Related]
48. Does full sternotomy have more significant impact than the cardiopulmonary bypass time in patients of mitral valve surgery?
Qiu Z; Chen X; Xu Y; Huang F; Xiao L; Yang T; Yin L
J Cardiothorac Surg; 2018 Apr; 13(1):29. PubMed ID: 29653554
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of heparin-coated circuits with full heparin dose strategy.
Sinci V; Kalaycioglu S; Gunaydin S; Imren Y; Gokgoz L; Soncul H; Ersoz A
Ann Thorac Cardiovasc Surg; 1999 Jun; 5(3):156-63. PubMed ID: 10413761
[TBL] [Abstract][Full Text] [Related]
50. Autotransfusion management during and after cardiopulmonary bypass alters fibrin degradation and transfusion requirements.
Wiefferink A; Weerwind PW; van Heerde W; Teerenstra S; Noyez L; de Pauw BE; Brouwer RM
J Extra Corpor Technol; 2007 Jun; 39(2):66-70. PubMed ID: 17672185
[TBL] [Abstract][Full Text] [Related]
51. A comparison of haemostatic biomarkers during low-risk patients undergoing cardiopulmonary bypass using either conventional centrifugal cell salvage or the HemoSep device.
Boyle G; Kuffel A; Parmar K; Gibson K; Smith M; Grehan A; Hunt BJ; Chambers DJ
Perfusion; 2019 Jan; 34(1):76-83. PubMed ID: 30067140
[TBL] [Abstract][Full Text] [Related]
52. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass.
Yamada H; Kudoh I; Hirose Y; Toyoshima M; Abe H; Kurahashi K
Acta Anaesthesiol Scand; 1996 Mar; 40(3):311-7. PubMed ID: 8721461
[TBL] [Abstract][Full Text] [Related]
53. In vivo comparison study of FDA-approved surface-modifying additives and poly-2-methoxyethylacrylate circuit surfaces coatings during cardiopulmonary bypass.
Ask A; Holt D; Smith L
J Extra Corpor Technol; 2006 Mar; 38(1):27-32. PubMed ID: 16637520
[TBL] [Abstract][Full Text] [Related]
54. Clinical effects of the heparin coated surface in cardiopulmonary bypass.
Svenmarker S; Sandström E; Karlsson T; Jansson E; Häggmark S; Lindholm R; Appelblad M; Aberg T
Eur J Cardiothorac Surg; 1997 May; 11(5):957-64. PubMed ID: 9196315
[TBL] [Abstract][Full Text] [Related]
55. Antegrade rapid prime displacement in elective coronary artery surgery is associated with lower perioperative blood transfusions and a shorter hospital stay.
Ariyaratnam P; Bennett RT; McLean LA; Jagannadham KK; Turner E; Griffin S; Chaudhry MA; Loubani M
Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):485-91. PubMed ID: 23690433
[TBL] [Abstract][Full Text] [Related]
56. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system.
Tayama E; Hayashida N; Akasu K; Kosuga T; Fukunaga S; Akashi H; Kawara T; Aoyagi S
Artif Organs; 2000 Aug; 24(8):618-23. PubMed ID: 10971248
[TBL] [Abstract][Full Text] [Related]
57. The effect of preoperative clopidogrel on bleeding after coronary artery bypass surgery.
Kang W; Theman TE; Reed JF; Stoltzfus J; Weger N
J Surg Educ; 2007; 64(2):88-92. PubMed ID: 17462208
[TBL] [Abstract][Full Text] [Related]
58. Influence of two blood conservation techniques (cardiotomy reservoir versus cell-saver) on biocompatibility of the heparin coated cardiopulmonary bypass circuit during coronary revascularization surgery.
Borowiec JW; Bozdayi M; Jaramillo A; Nilsson L; Venge P; Henze A
J Card Surg; 1997; 12(3):190-7. PubMed ID: 9395949
[TBL] [Abstract][Full Text] [Related]
59. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome.
Svenmarker S; Häggmark S; Jansson E; Lindholm R; Appelblad M; Sandström E; Aberg T
Scand Cardiovasc J; 2002 Aug; 36(4):241-6. PubMed ID: 12201973
[TBL] [Abstract][Full Text] [Related]
60. Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.
Gunaydin S; McCusker K; Sari T; Onur MA; Zorlutuna Y
Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):371-6. PubMed ID: 20026488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
